



New Strategies to Manage Residual Risk beyond Statin Therapy in Patients with or at High Risk of Cardiovascular Events

Dear Grand Rounds Administrator:

In conjunction with the Postgraduate Institute for Medicine (PIM), Medtelligence is pleased to announce a highly informative, rigorous, CME-certified Grand Rounds program. This initiative is supported by an educational grant from Amarin Pharma, Inc.

This unique program will bring a distinguished specialist to your center to provide evidence-based information and guidance on the management of residual risk in patients with, or at high risk of, cardiovascular events.

The target audience includes family and general practitioners, internists, cardiologists, endocrinologists, diabetologists, hospitalists, fellows, and allied health professionals.

The Learning Objectives are designed to enhance participants' ability to:

- Evaluate the risk of atherosclerotic cardiovascular disease (ASCVD) events
- Describe major predictors of residual ASCVD risk, which can remain despite guideline-driven statin monotherapy
- Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk in patients with TG elevation while on statins

Jointly provided by Postgraduate Institute for Medicine (PIM) and Medtelligence, this program is certified for 1.0 *AMA PRA Category 1 Credit(s)*TM. A list of available faculty and instructions for requesting a Grand Rounds Lecture Program are enclosed.

We hope your institution will take advantage of this important teaching initiative.

Sincerely,
Michael Miller, MD
Professor of Cardiovascular Medicine,
Epidemiology & Public Health
University of Maryland School of Medicine

Ben Caref, PhD
Chief Medical Officer
Medtelligence



500 Office Center Drive, Suite 300, Fort Washington, PA 19034

New Strategies to Manage Residual Risk beyond Statin Therapy in Patients with or at High Risk of Cardiovascular Events

Grand Rounds Program

This program is designed by distinguished experts to provide evidence-based information and guidance on the management of residual risk in patients with, or at high risk of, cardiovascular events.

Target Audience

This activity is intended for Family and General Practitioners, Internists, Cardiologists, Endocrinologists, Diabetologists, Hospitalists, Fellows, and allied health professionals involved in the care of patients with elevated triglycerides and lipid disorders.

Learning Objectives

- Evaluate the risk of atherosclerotic cardiovascular disease (ASCVD) events
- Describe major predictors of residual ASCVD risk, which can remain despite guideline-driven statin monotherapy
- Apply evidence-based guidelines and recent randomized clinical trial evidence to reduce residual ASCVD risk in patients with TG elevation while on statins

Sponsorship

Jointly provided by Postgraduate Institute for Medicine (PIM) and Medtelligence.

Support

This activity is supported by an educational grant from Amarin Pharma, Inc.

Program Administration

Medtelligence

Accreditation through PIM

For PIM to accredit a lecture at your institution, the following Medtelligence-supplied documents must be completed and returned to Medtelligence at the conclusion of the program: Sign-in sheet and Evaluations.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

To request a program, please complete the enclosed **Program Request Form (PRF)** and refer to the list of faculty members (also enclosed) to indicate your speaker preference. Please fax or email the completed PRF to:

FAX: 206-333-1106

EMAIL: jfreeman@medtelligence.net

Please contact Jill Freeman with any questions: jfreeman@medtelligence.net

New Strategies to Manage Residual Risk beyond Statin Therapy in Patients with or at High Risk of Cardiovascular Events

Faculty

Christie M. Ballantyne, MD

Chief, Sections of Cardiology & Cardiovascular Research
Professor and Vice Chair of Research
J. S. Abercrombie Chair, Atherosclerosis
& Lipoprotein Research
Department of Medicine
Director, Center for Cardiometabolic Disease Prevention
Baylor College of Medicine
Houston, TX

Harold E. Bays, MD

Medical Director / President
L-MARC Research Center
Louisville, KY

Vera A. Bittner, MD, MSPH

Professor of Medicine
Section Head, General Cardiology, Prevention and
Imaging
Medical Director, Coronary Care Unit and Cardiac
Rehabilitation Program
Department of Medicine, Division of Cardiovascular
Disease
University of Alabama at Birmingham
Birmingham, AL

Eliot A. Brinton, MD

President
Utah Lipid Center
Salt Lake City, UT

Matthew J. Budoff, MD

Professor of Medicine
David Geffen School of Medicine at UCLA
Endowed Chair of Preventive Cardiology
Program Director, Division of Cardiology
Los Angeles Biomedical Research Institute
Torrance, CA

Robert J. Chilton, DO

Professor of Medicine, School of Medicine
Director of Catheterization Laboratory and
Electrophysiology Laboratory
Director of Clinical Proteomics Center
University of Texas Health Science Center
San Antonio, TX

Robert J. Cooper, MD

Endocrinologist
Baystate Medical Center
Springfield, MA
Assistant Professor of Medicine
Tufts University School of Medicine
Boston, MA

Mahfouz El Shahawy, MD, MS

President, International Society of Cardiovascular Disease
Prevention
Clinical Professor of Medicine, Universities of Florida and
South Florida
Medical Director, Cardiovascular Health Assessment
Center
President, Cardiovascular Center of Sarasota
Sarasota, FL

Sergio Fazio, MD, PhD

William and Sonja Connor Chair of Preventive Cardiology
Professor of Medicine, Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

Kenneth R. Feingold, MD

Professor Emeritus
University of California, San Francisco
San Francisco, CA

Terry A. Jacobson, MD

Director, Lipid Clinic and Cardiovascular Risk Reduction
Program
Professor of Medicine
Emory University
Atlanta, GA

Peter H. Jones, MD

Associate Professor of Medicine
Center for Cardiovascular Disease Prevention
Baylor College of Medicine
Medical Director, Weight Management Center
Director, Lipid Metabolism and Atherosclerosis Clinic
Houston Methodist
Houston, TX

MacRae F. Linton, MD

Stephen and Mary Schillig Chair in Medicine
Director, Prevention and Lipid Management Program
Vanderbilt University Medical Center
Professor of Medicine
Professor of Pharmacology
Vanderbilt University School of Medicine
Nashville, TN

Michael Miller, MD

Professor of Cardiovascular Medicine, Epidemiology &
Public Health
University of Maryland School of Medicine
University of Maryland Medical Center
Baltimore, MD



New Strategies to Manage Residual Risk beyond Statin Therapy in Patients with or at High Risk of Cardiovascular Events

Faculty, *cont.*

John R. Nelson, MD

Director, California Cardiovascular Institute
CA-ACC-Governmental Relations Committee Member
Fresno, CA

Michael Ozner, MD

Medical Director, Center for Prevention and Wellness
Baptist Health South Florida
Voluntary Assistant Professor of Medicine (Cardiology)
University of Miami Miller School of Medicine
Miami, FL

Gregory S. Pokrywka, MD

Assistant Professor of General Internal Medicine
Johns Hopkins University School of Medicine
Director, Baltimore Lipid Center
Diplomate, American Board of Clinical Lipidology
Towson, MD

Paul D. Rosenblit, MD, PhD

Director and Site Principal Investigator
Diabetes/Lipid Management and Research Center
Huntington Beach, CA
Clinical Professor of Medicine
Division of Endocrinology, Diabetes and Metabolism
University of California, Irvine (UCI) School of Medicine
Irvine, CA
Co-Director, Diabetes Out-Patient Clinic
UCI Medical Center
Orange, CA

Michael D. Shapiro, DO

Associate Professor of Medicine
Division of Cardiovascular Medicine
Director, Cardiac MRI and CT Program
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

Laurence S. Sperling, MD

Professor of Medicine (Cardiology)
Founder and Director of Preventive Cardiology
Co-Director, Cardiovascular Disease Fellowship Program
Emory University School of Medicine
Atlanta, GA

Paul D. Thompson, MD

Chief of Cardiology
Co-Physician-in-Chief
Hartford HealthCare Heart & Vascular Institute
Hartford Hospital
Hartford, CT
Professor of Medicine
University of Connecticut School of Medicine
Farmington, CT

Howard S. Weintraub, MD

Clinical Professor of Medicine
New York University School of Medicine
Clinical Director, NYU Center for the Prevention of
Cardiovascular Disease
New York, NY

Nanette K. Wenger, MD

Professor of Medicine (Cardiology)
Emory University School of Medicine
Consultant, Emory Heart and Vascular Center
Founding Consultant, Emory Women's Heart Center
Atlanta, GA

Nathan D. Wong, PhD

Professor and Director
Heart Disease Prevention Program
Division of Cardiology
University of California, Irvine School of Medicine
Irvine, CA

R. Scott Wright, MD

Professor of Medicine
Division of Cardiovascular Diseases
Mayo Clinic
Rochester, MN

**New Strategies to Manage Residual Risk Beyond Statin Therapy in Patients
with or at High Risk of Cardiovascular Events**

Program Request Form

Hospital/University Contact Name & Title:	Speaker Preference:
Contact Phone:	
Contact Fax:	
Department:	
Department Head:	
Department Head Title:	Will PIM certify your program? _____ Yes _____ No
Hospital/University Name:	If yes, we will produce flyers for distribution prior to the lecture. Please complete the required Flyer Information Form attached.
Hospital's Academic Affiliation:	
Address:	
City, State, Zip:	
Email:	Will speaker honoraria be paid by Medtelligence or the hospital? _____ Medtelligence _____ Hospital (Medtelligence will provide the check)
Proposed Dates:	If through the hospital, please supply the following:
Start Time: _____ AM / PM (Duration=1 hour)	Payee Name:
Estimated Audience:	Tax ID#:
Audience Specialty:	
Lecture Location/Room:	
Additional Comments:	

**PLEASE FAX OR EMAIL THE COMPLETED PROGRAM REQUEST FORM
(AND FLYER INFORMATION FORM, IF APPLICABLE)**

FAX: 206-333-1106

EMAIL: jfreeman@medtelligence.net



**New Strategies to Manage Residual Risk beyond Statin Therapy in Patients
with or at High Risk of Cardiovascular Events**

Flyer Information Form

Day of Week:

Date:

Start time: _____ AM / PM
(Duration = 1 hour)

Name of Lecture Institution:

Floor/Room Number:

Room Name:

Street Address:

City, State, Zip:

For more information, contact:

At phone number:

If you are requesting
CME credit through
PIM, you must
complete this form
and fax back with your
**Program Request
Form** attached.
Flyers are required.

**PLEASE FAX OR EMAIL THE COMPLETED FLYER
INFORMATION FORM
(AND PROGRAM REQUEST FORM)**

FAX: 206-333-1106
EMAIL: jfreeman@medtelligence.net